ArticleCell stress & chaperones2026
Urinary HSP90 as a non-invasive biomarker of active tubular injury in kidney transplant recipients: A multicenter prospective study.
Article in Cell stress & chaperones, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We previously demonstrated that serum heat shock protein 90 (HSP90) is a promising biomarker for severe acute allograft rejection involving vascular endothelial injury; however, the clinical significance of urinary HSP90 (uHSP90) remains unclear. We hypothesized that uHSP90 reflects acute T cell-mediated rejection (ATCMR), a common form of allograft rejection characterized by tubulitis. This multicenter prospective study included 262 paired urine and serum samples from 112 kidney transplant recipients, along with corresponding renal allograft biopsy specimens. uHSP90 levels were measured and normalized to urinary creatinine (uHSP90/Cr). Histopathological findings were evaluated according to the Banff (2022) classification, and HSP90 expression was assessed by immunohistochemistry. uHSP90/Cr levels were significantly elevated in conditions associated with active tubular injury, including ATCMR, calcineurin inhibitor nephropathy, and BK virus nephropathy, although they were not specific to ATCMR. uHSP90/Cr levels were significantly associated with Banff scores for interstitial inflammation, tubulitis, interstitial fibrosis, and tubular atrophy. In contrast, renal tissue HSP90 expression was significantly decreased and negatively correlated with uHSP90/Cr levels (ρ = -0.29, P < .001). uHSP90/Cr demonstrated moderate diagnostic performance for active tubular injury, with an area under the receiver operating characteristic curve of 0.713, comparable to that of β2-microglobulin and superior to that of N-acetyl-β-D-glucosaminidase. Multivariable analysis demonstrated that detectable uHSP90 was independently associated with active tubular injury (odds ratio, 4.93; 95% confidence interval, 2.21-11.00; P < .001). These findings suggest that uHSP90 may serve as a biomarker of renal allograft tubular injury, although it is not specific for allograft rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.